Hoffmann-la Roche Inc.

F. Hoffmann-la Roche Ag

Baoxia Wang

Hongying Yun

Lisha Wang

Xiufang Zheng

Lu Gao

Song Feng

Chao Li

Dongdong Chen

Weixing Zhang

Chungen Liang

Lei Guo

Wei Zhu

Sung-Sau So

Fariborz Firooznia

Guolong Wu

Tai-An Lin

Mengwei Huang

The present invention relates to compounds of formula (I), wherein R, Rand Rare as described herein, and their prodrugs or pharmaceutically acceptable salt, enantiomer or diastereomer thereof, and compositions including the compounds and methods of using the compounds.

Process for making 3-substituted 5-amino-6H-thiazolo[4,5-d]pyrimidine-2, 7-dione compounds useful for the treatment of virus infection

3-substituted 5-amino-6H-thiazolo[4,5-D]pyrimidine-2, 7-dione compounds for the treatment and prophylaxis of virus infection

The invention provides novel compounds having the general formula: wherein R, R, R, R, R, R, W, W, W, A and X are as described herein, compositions including the compounds and methods of using the compounds for the treatment and prophylaxis of respiratory syncytial virus infection.

Aza-oxo-indoles for the treatment and prophylaxis of respiratory syncytial virus infection

The present invention relates to compounds of formula (I), wherein Rto Rare as described herein, and their prodrugs or pharmaceutically acceptable salt, enantiomer or diastereomer thereof, and compositions including the compounds and methods of using the compounds.

Substituted aminothiazolopyrimidinedione for the treatment and prophylaxis of virus infection

3-substituted 5-amino-6H-thiazolo[4,5-d]pyrimidine-2,7-dione compounds for the treatment and prophylaxis of virus infection

The invention provides novel compounds having the general formula: wherein R, R, R, R, W and X are as described herein, compositions including the compounds and methods of using the compounds.

3-substituted 5-amino-6H-thiazolo[4,5-D]pyrimidine-2,7-dione compounds for the treatment and prophylaxis of virus infection

The invention is concerned with the compounds of formula I: and pharmaceutically acceptable salts and esters thereof, wherein X, Q and R-Rare defined in the detailed description and claims. The invention is also concerned with the compounds of formula Z: and pharmaceutically acceptable salts and esters thereof, wherein R-Rare defined in the detailed description and claims. In addition, the present invention relates to methods of manufacturing and using the compounds of formula I and Z as well as pharmaceutical compositions containing such compounds. The compounds of formula I and Z are antagonists or partial agonists at the CRTH2 receptor and may be useful in treating diseases and disorders associated with that receptor such as asthma.

Naphthylacetic acids

Growing community of inventors

Shanghai, China

Baoxia Wang